Alaide Morcavallo

Oncology Targeted Discovery, Oncology R&D, AstraZeneca
Cambridge, ENG CB20AA, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications

An Inducible BRCA1 Expression System with In Vivo Applicability Uncovers Activity of the Combination of ATR and PARP Inhibitors to Overcome Therapy Resistance.

An Inducible BRCA1 Expression System with In Vivo Applicability Uncovers Activity of the Combination of ATR and PARP Inhibitors to Overcome Therapy Resistance.

Journal: Cancers
Published: December 12, 2025

The ITCC-P4 PDX Platform Enables Preclinical Testing of Pediatric Cancers.

The ITCC-P4 PDX Platform Enables Preclinical Testing of Pediatric Cancers.

Journal: Cancer research
Published: November 19, 2025

MIF-CD74 signaling drives immune modulation in medulloblastoma.

MIF-CD74 signaling drives immune modulation in medulloblastoma.

Journal: Neuro-oncology
Published: June 13, 2025

MIF-CD74 signaling drives immune modulation in medulloblastoma.

MIF-CD74 signaling drives immune modulation in medulloblastoma.

Journal: Neuro-oncology
Published: June 13, 2025

Investigation of a global mouse methylome atlas reveals subtype-specific copy number alterations in pediatric cancer models.

Investigation of a global mouse methylome atlas reveals subtype-specific copy number alterations in pediatric cancer models.

Journal: Nature genetics
Published: December 06, 2024

MYC-dependent upregulation of the de novo serine and glycine synthesis pathway is a targetable metabolic vulnerability in group 3 medulloblastoma.

MYC-dependent upregulation of the de novo serine and glycine synthesis pathway is a targetable metabolic vulnerability in group 3 medulloblastoma.

Journal: Neuro-oncology
Published: October 08, 2024

Correction: Suppression of progranulin expression inhibits bladder cancer growth and sensitizes cancer cells to cisplatin.

Correction: Suppression of progranulin expression inhibits bladder cancer growth and sensitizes cancer cells to cisplatin.

Journal: Oncotarget
Published: October 01, 2024

Retraction Note: Tumor necrosis factor overcomes immune evasion in p53-mutant medulloblastoma.

Retraction Note: Tumor necrosis factor overcomes immune evasion in p53-mutant medulloblastoma.

Journal: Nature neuroscience
Published: December 15, 2021

Biological Role of MYCN in Medulloblastoma: Novel Therapeutic Opportunities and Challenges Ahead.

Biological Role of MYCN in Medulloblastoma: Novel Therapeutic Opportunities and Challenges Ahead.

Journal: Frontiers in oncology
Published: April 12, 2021

Discoidin Domain Receptor 1 functionally interacts with the IGF-I system in bladder cancer.

Discoidin Domain Receptor 1 functionally interacts with the IGF-I system in bladder cancer.

Journal: Matrix biology plus
Published: December 12, 2019

Tumor necrosis factor overcomes immune evasion in p53-mutant medulloblastoma.

Tumor necrosis factor overcomes immune evasion in p53-mutant medulloblastoma.

Journal: Nature neuroscience
Published: January 23, 2019

Suppression of progranulin expression inhibits bladder cancer growth and sensitizes cancer cells to cisplatin.

Suppression of progranulin expression inhibits bladder cancer growth and sensitizes cancer cells to cisplatin.

Journal: Oncotarget
Published: January 21, 2016
Showing 1-12 of 22

Last Updated: 09/26/2026